Dechra Pharmaceuticals (LON:DPH)‘s stock had its “add” rating reissued by equities researchers at Numis Securities in a research note issued to investors on Thursday. They presently have a GBX 2,260 ($30.65) target price on the stock. Numis Securities’ price objective suggests a potential upside of 11.99% from the stock’s current price.
Separately, Jefferies Group reissued a “hold” rating and issued a GBX 2,221 ($30.12) price objective on shares of Dechra Pharmaceuticals in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Dechra Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of GBX 1,904.50 ($25.83).
Shares of Dechra Pharmaceuticals (LON:DPH) traded up GBX 23 ($0.31) during mid-day trading on Thursday, hitting GBX 2,018 ($27.37). The stock had a trading volume of 123,576 shares, compared to its average volume of 123,193. The firm has a market capitalization of $1,880.00 and a price-to-earnings ratio of 7,207.14. Dechra Pharmaceuticals has a fifty-two week low of GBX 1,396 ($18.93) and a fifty-two week high of GBX 2,272 ($30.81).
Dechra Pharmaceuticals Company Profile
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.